Working… Menu

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02580305
Recruitment Status : Completed
First Posted : October 20, 2015
Last Update Posted : November 23, 2020
Information provided by (Responsible Party):
Suven Life Sciences Limited

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 5, 2019
Actual Study Completion Date : November 7, 2019
Certification/Extension First Submitted : November 3, 2020